Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2024 ...
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...
emjreviews.com6 天
Propranolol’s Surprising Role in Reducing Parkinson’s Tremor
Propranolol reduces Parkinson’s tremor and motor cortex activity, suggesting a new therapeutic approach beyond stress ...
Opening Day: Infinity Natural Resources valued at $1.3B in market debut
Shares of Infinity Natural Resources jumped almost 11% in their NYSE debut, valuing the oil and natural gas producer at $1.3B. The listing ...
Roche Q4 Earnings Review: Solid All-Court Performance, But Quiet On GLP-1 Progress
Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...
idw6 天
Research: β-Glucans Promising Adjuvants for Allergy Treatment
The results indicate that β-glucans can target the immune system and modulate pro-inflammatory responses. Their potential to suppress allergic reactions and offer new approaches to allergy treatment ...